Company intelligence / Profile preview

16 Bit

Toronto, Ontario, Canada

Ownership: Private
Development stage: Commercial

Overview

16 Bit has developed Rho™, an AI-enabled software that analyzes standard x-rays to opportunistically screen for low bone mineral density, aiding early osteoporosis detection. Rho™ received FDA De Novo marketing authorization in April 2024 and is also licensed by Health Canada. Their Physis™ product provides automated pediatric bone age estimation, validated by multiple peer-reviewed studies and global clinical use.

Therapeutic areas: Endocrinology
Modalities: DeviceArtificial intelligence software as a medical device (SaMD)
Industry: Medical Imaging

Drug pipeline

2 assets

Rho

Commercial

Indications: Low bone mineral density screening

1 more asset in the full pipeline.

Request access →

Partnerships

Clear Medical ImagingMitacs academic collaboration programCAN Health Network support/involvementINOVAIT support/involvement

Beyond the preview

Go deeper on 16 Bit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 16 Bit.

Explore the full profile